Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 2/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.65 |
| ▸ | CLCN2 | P51788 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | TTR | P02766 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | FABP2 | P12104 | 1/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terofenamate SCHEMBL4742611 | 0.97 | METTL3 (0.79) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL49245 | 0.97 | METTL3 (0.83) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL5089764 | 0.96 | METTL3 (0.81) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL9856559 | 0.96 | METTL3 (0.81) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL29483481 | 0.96 | METTL3 (0.84) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL26088 | 0.96 | METTL3 (0.84) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL9659644 | 0.95 | METTL3 (0.76) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL9425148 | 0.95 | METTL3 (0.76) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL3805644 | 0.95 | METTL3 (0.79) | METTL3PTGS2CLCN2MEN1MAPK1 | |
| Terofenamate SCHEMBL16760954 | 0.95 | METTL3 (0.79) | METTL3PTGS2CLCN2MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321809-B2 | Macrocyclic compounds for suppressing replication of hepatitis C virus | GINKGO PHARAMA CO., LTD. (CN) | 2016-04-26 | — | — | US | disclosed |
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2015-01-29 | — | — | US | disclosed |
| EP-2816054-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | GINKGO PHARMA CO., LTD. (CN) | 2014-12-24 | — | — | EP | disclosed |
| US-6399808-B1 | REACTING AMINE WITH CARBON DIOXIDE IN ANHYDROUS SOLVENT | UNIVERSITY OF SOUTH FLORIDA | 2002-06-04 | — | — | US | disclosed |
| WO-2000050389-A1 | EFFICIENT CARBAMATE SYNTHESIS | UNIVERSITY OF SOUTH FLORIDA (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031603-A1 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS | HCCS, HAVCR2, EIF2AK2 | METTL3 3554/4885PTGS2 2272/4885CLCN2 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.